Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Withdrawn 1Unknown 1Suspended 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 473Prostatic Neoplasms 423Neoplasms 384Multiple Myeloma 266Colorectal Neoplasms 257Lung Neoplasms 245Neoplasm Metastasis 234Melanoma 219Leukemia, Myeloid, Acute 193Ovarian Neoplasms 189Pancreatic Neoplasms 177Squamous Cell Carcinoma of Head and Neck 160Carcinoma, Renal Cell 146Recurrence 144Lymphoma 144Glioblastoma 142Lymphoma, Non-Hodgkin 136Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Leukemia, Lymphocytic, Chronic, B-Cell 123Brain Neoplasms 123Carcinoma, Hepatocellular 122Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Urinary Bladder Neoplasms 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Lymphoma, Large B-Cell, Diffuse 104Sarcoma 103Lymphoma, Follicular 100

Interventions

Vorinostat 1Lenalidomide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × GATA2 Deficiency × Clear all
NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡